Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.Bone marrow transplantation · 2020
   Review
2. Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq.Open access rheumatology : research and reviews · 2019
   Review
3. The Use of Biosimilars in the Middle East: Review Article.Current rheumatology reports · 2018
   Review
4. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.Clinical rheumatology · 2018
   Review
5. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran.Iranian journal of pharmaceutical research : IJPR · 2016
   Article
6. Impacts of international sanctions on Iranian pharmaceutical market.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013
   Article
7. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.